-
Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion
•
Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of its expanded manufacturing plant in Shanghai, China. The expansion, which was completed in 15 months, is set to significantly enhance the company’s manufacturing capabilities by doubling its current capacity. Shanghai Plant’s Strategic ImportanceThe firm’s China…
-
Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million
•
Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total consideration of USD 477.6 million. The deal comprises USD 387.4 million in cash and USD 90.2 million in Contingent Value Rights (CVRs), with the transaction expected to close in the first quarter of 2024. Acquisition…
